Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis.
BACKGROUND: Antibodies to aquaporin-4 (AQP4-Ab) are found in 60-80% of patients with neuromyelitis optica (NMO), a severely disabling inflammatory CNS disorder of putative autoimmune aetiology, which predominantly affects the optic nerves and spinal cord. OBJECTIVE: To assess the frequency of AQP4-...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| 格式: | Journal article |
| 語言: | English |
| 出版: |
2010
|
| _version_ | 1826298506949689344 |
|---|---|
| author | Jarius, S Frederikson, J Waters, P Paul, F Akman-Demir, G Marignier, R Franciotta, D Ruprecht, K Kuenz, B Rommer, P Kristoferitsch, W Wildemann, B Vincent, A |
| author_facet | Jarius, S Frederikson, J Waters, P Paul, F Akman-Demir, G Marignier, R Franciotta, D Ruprecht, K Kuenz, B Rommer, P Kristoferitsch, W Wildemann, B Vincent, A |
| author_sort | Jarius, S |
| collection | OXFORD |
| description | BACKGROUND: Antibodies to aquaporin-4 (AQP4-Ab) are found in 60-80% of patients with neuromyelitis optica (NMO), a severely disabling inflammatory CNS disorder of putative autoimmune aetiology, which predominantly affects the optic nerves and spinal cord. OBJECTIVE: To assess the frequency of AQP4-Ab in patients with optic neuritis (ON), and to investigate the prognostic implications of AQP4-Ab seropositivity in such patients. PATIENTS AND METHODS: AQP4-Ab serum levels were determined in 224 individuals from Austria, Denmark, France, Germany, Italy, and Turkey using a newly developed fluorescence immunoprecipitation assay employing recombinant human AQP4. RESULTS: AQP4-Ab were detectable in 8/139 (5.8%) patients with acute monosymptomatic optic neuritis (AMON) and in 10/17 (58.8%) patients with established NMO and a last relapse of acute ON (NMO/ON), but not in 32 patients with multiple sclerosis or in 36 healthy controls. At last examination, 4/8 (50%) seropositive AMON patients had met the criteria for NMO but 0/128 seronegative AMON patients. Disease severity differed significantly between seropositive and seronegative AMON. Complete bilateral or unilateral blindness occurred in six AQP4-Ab positive patients, but only in one AQP4-Ab negative patient. AQP4-Ab levels did not vary between seropositive AMON and NMO/ON and did not correlate with disease severity. Female gender, a relapsing course, and concomitant autoimmunity were associated with AQP4-Ab seropositive status and risk of developing NMO. CONCLUSION: AQP4-Ab is relatively rare among patients with AMON, but if present it predicts a high rate of conversion to NMO within one year. |
| first_indexed | 2024-03-07T04:47:54Z |
| format | Journal article |
| id | oxford-uuid:d3f11ff1-cbdc-4a70-8e5e-ff7a98e82db4 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:47:54Z |
| publishDate | 2010 |
| record_format | dspace |
| spelling | oxford-uuid:d3f11ff1-cbdc-4a70-8e5e-ff7a98e82db42022-03-27T08:14:56ZFrequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:d3f11ff1-cbdc-4a70-8e5e-ff7a98e82db4EnglishSymplectic Elements at Oxford2010Jarius, SFrederikson, JWaters, PPaul, FAkman-Demir, GMarignier, RFranciotta, DRuprecht, KKuenz, BRommer, PKristoferitsch, WWildemann, BVincent, A BACKGROUND: Antibodies to aquaporin-4 (AQP4-Ab) are found in 60-80% of patients with neuromyelitis optica (NMO), a severely disabling inflammatory CNS disorder of putative autoimmune aetiology, which predominantly affects the optic nerves and spinal cord. OBJECTIVE: To assess the frequency of AQP4-Ab in patients with optic neuritis (ON), and to investigate the prognostic implications of AQP4-Ab seropositivity in such patients. PATIENTS AND METHODS: AQP4-Ab serum levels were determined in 224 individuals from Austria, Denmark, France, Germany, Italy, and Turkey using a newly developed fluorescence immunoprecipitation assay employing recombinant human AQP4. RESULTS: AQP4-Ab were detectable in 8/139 (5.8%) patients with acute monosymptomatic optic neuritis (AMON) and in 10/17 (58.8%) patients with established NMO and a last relapse of acute ON (NMO/ON), but not in 32 patients with multiple sclerosis or in 36 healthy controls. At last examination, 4/8 (50%) seropositive AMON patients had met the criteria for NMO but 0/128 seronegative AMON patients. Disease severity differed significantly between seropositive and seronegative AMON. Complete bilateral or unilateral blindness occurred in six AQP4-Ab positive patients, but only in one AQP4-Ab negative patient. AQP4-Ab levels did not vary between seropositive AMON and NMO/ON and did not correlate with disease severity. Female gender, a relapsing course, and concomitant autoimmunity were associated with AQP4-Ab seropositive status and risk of developing NMO. CONCLUSION: AQP4-Ab is relatively rare among patients with AMON, but if present it predicts a high rate of conversion to NMO within one year. |
| spellingShingle | Jarius, S Frederikson, J Waters, P Paul, F Akman-Demir, G Marignier, R Franciotta, D Ruprecht, K Kuenz, B Rommer, P Kristoferitsch, W Wildemann, B Vincent, A Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. |
| title | Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. |
| title_full | Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. |
| title_fullStr | Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. |
| title_full_unstemmed | Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. |
| title_short | Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. |
| title_sort | frequency and prognostic impact of antibodies to aquaporin 4 in patients with optic neuritis |
| work_keys_str_mv | AT jariuss frequencyandprognosticimpactofantibodiestoaquaporin4inpatientswithopticneuritis AT frederiksonj frequencyandprognosticimpactofantibodiestoaquaporin4inpatientswithopticneuritis AT watersp frequencyandprognosticimpactofantibodiestoaquaporin4inpatientswithopticneuritis AT paulf frequencyandprognosticimpactofantibodiestoaquaporin4inpatientswithopticneuritis AT akmandemirg frequencyandprognosticimpactofantibodiestoaquaporin4inpatientswithopticneuritis AT marignierr frequencyandprognosticimpactofantibodiestoaquaporin4inpatientswithopticneuritis AT franciottad frequencyandprognosticimpactofantibodiestoaquaporin4inpatientswithopticneuritis AT ruprechtk frequencyandprognosticimpactofantibodiestoaquaporin4inpatientswithopticneuritis AT kuenzb frequencyandprognosticimpactofantibodiestoaquaporin4inpatientswithopticneuritis AT rommerp frequencyandprognosticimpactofantibodiestoaquaporin4inpatientswithopticneuritis AT kristoferitschw frequencyandprognosticimpactofantibodiestoaquaporin4inpatientswithopticneuritis AT wildemannb frequencyandprognosticimpactofantibodiestoaquaporin4inpatientswithopticneuritis AT vincenta frequencyandprognosticimpactofantibodiestoaquaporin4inpatientswithopticneuritis |